The Role of Incorporating Acacia Gum in Foods on Glucose Homeostasis in Healthy Humans
AcaciaGlu
2 other identifiers
interventional
14
1 country
1
Brief Summary
Abnormal postprandial blood glucose (PPG) is considered as a strong predictor for developing metabolic diseases worldwide. Nowadays, little understanding is available on how a carbohydrate-rich food matrix and the starch structures within interact with the gastrointestinal tract to help in controlling PPG. In this investigation, the use Acacia gum enriched flour will be used to explore the effect of adding the gum as food supplement on PPG in healthy humans.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jun 2023
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 30, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
September 30, 2023
CompletedFirst Submitted
Initial submission to the registry
January 30, 2026
CompletedFirst Posted
Study publicly available on registry
February 18, 2026
CompletedFebruary 18, 2026
February 1, 2026
3 months
January 30, 2026
February 10, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
postprandial blood glucose
0 minutes and postprandial timepoints: 15 minutes, 30 minutes, 60 minutes,120 minutes,180 minutes
Study Arms (2)
Acacia gum incorporated biscuits
EXPERIMENTALAcacia gum incorporated biscuits
control biscuits
NO INTERVENTIONcontrol biscuits
Interventions
incorporating acacia gum flour into commonly consume foods
Eligibility Criteria
You may qualify if:
- Male and female self-reported healthy volunteers (aged 18 to 40 years)
- Normal to overweight individuals (body mass index (BMI) 18.5-30 kg/m2) o BMI is equal to body weight (kg) divided by height squared (m2)
You may not qualify if:
- History of substance abuse
- Excessive alcohol intake
- Pregnancy
- Diabetes
- Cardiovascular disease
- Cancer
- Any gastrointestinal disease e.g. irritable bowel syndrome or inflammatory bowel disease
- Kidney disease
- Liver disease
- Pancreatitis
- Use of medications likely to interfere with energy metabolism, appetite regulation and hormonal balance, including: anti-inflammatory drugs or steroids, antibiotics, androgens, phenytoin, erythromycin or thyroid hormones.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
King Fahd Medical Research center
Jeddah, Saudi Arabia
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- PREVENTION
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Dr.
Study Record Dates
First Submitted
January 30, 2026
First Posted
February 18, 2026
Study Start
June 1, 2023
Primary Completion
August 30, 2023
Study Completion
September 30, 2023
Last Updated
February 18, 2026
Record last verified: 2026-02
Data Sharing
- IPD Sharing
- Will not share